First Community Trust NA Sells 800 Shares of Pfizer Inc. $PFE

First Community Trust NA lessened its holdings in Pfizer Inc. (NYSE:PFE) by 2.9% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 26,397 shares of the biopharmaceutical company’s stock after selling 800 shares during the period. First Community Trust NA’s holdings in Pfizer were worth $640,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Trust Co of the South raised its position in Pfizer by 1.5% in the second quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company’s stock worth $712,000 after purchasing an additional 441 shares in the last quarter. William B. Walkup & Associates Inc. grew its stake in shares of Pfizer by 1.2% during the fourth quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company’s stock valued at $1,044,000 after purchasing an additional 454 shares during the last quarter. Members Trust Co grew its stake in shares of Pfizer by 2.1% during the first quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company’s stock valued at $587,000 after purchasing an additional 467 shares during the last quarter. Sutton Place Investors LLC lifted its holdings in Pfizer by 5.6% in the first quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company’s stock valued at $224,000 after buying an additional 472 shares during the period. Finally, MSH Capital Advisors LLC lifted its holdings in Pfizer by 1.4% in the first quarter. MSH Capital Advisors LLC now owns 34,585 shares of the biopharmaceutical company’s stock valued at $876,000 after buying an additional 485 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Down 3.8%

PFE opened at $23.91 on Friday. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43. The company has a fifty day moving average price of $24.79 and a two-hundred day moving average price of $24.28. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company has a market cap of $135.94 billion, a P/E ratio of 12.72, a price-to-earnings-growth ratio of 0.88 and a beta of 0.55.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the previous year, the business posted $0.60 EPS. Pfizer’s quarterly revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were paid a $0.43 dividend. The ex-dividend date was Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 7.2%. Pfizer’s dividend payout ratio is presently 91.49%.

Analyst Upgrades and Downgrades

PFE has been the topic of several analyst reports. HSBC cut their target price on shares of Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a report on Monday, May 19th. Morgan Stanley lifted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Bank of America lifted their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Jefferies Financial Group lifted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock a “buy” rating in a research note on Wednesday, May 21st. Finally, Citigroup boosted their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.